The work behind the name.
Nyxoah develops the Genio hypoglossal nerve stimulation system for obstructive sleep apnea. The company reports U.S. FDA marketing approval in August 2025, supporting its American commercial activity. Its investor communications and product channels provide information on clinical evidence, market expansion and physician adoption. These developments are relevant to ENT surgeons and sleep program operators.
WHY FOLLOW
Its Genio system adds another implant-based platform to the U.S. sleep-apnea market.
